I4V-MC-JAJK: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Preserve Beta Cell Function in Participants Newly Diagnosed With Type 1 Diabetes Aged ≥1 to <36 Years

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522170-36-00

Enrollment

Registered

2026-02-02

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 1

Brief summary

Change from Baseline in C-peptide Area Under the Curve (AUC) [Time Frame: Baseline, Week 52]

Interventions

DRUGBARICITINIB

DRUGPlacebo to match LY

DRUGBaricitinib

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Change from Baseline in C-peptide Area Under the Curve (AUC) [Time Frame: Baseline, Week 52]	—

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026